PP405 for hair loss is generating growing interest as an investigational topical compound targeting the Wnt signalling pathway — a mechanism distinct from existing licensed treatments such as minoxidil and finasteride. Primarily researched for androgenetic alopecia (AGA), the most common cause of hair loss in both men and women, PP405 aims to reactivate dormant follicles and extend the active growth phase. However, it remains in clinical development and has not received marketing authorisation from the MHRA or EMA. This article explains how PP405 works, its potential applications, safety considerations, and how to access it appropriately in the UK.
Summary: PP405 is an investigational topical compound being studied for androgenetic alopecia that works by activating the Wnt signalling pathway to stimulate hair follicle growth, but it is not yet licensed in the UK.
- PP405 acts as a Wnt pathway activator, aiming to transition dormant follicles into the active anagen (growth) phase.
- It is primarily being investigated for androgenetic alopecia (AGA) in both men and women, and does not directly target androgen pathways.
- PP405 has not received marketing authorisation from the MHRA or EMA and is not available through NHS prescribing or standard UK pharmacies.
- Its full safety profile has not been established; as a topical agent, local skin reactions are the most likely side effects, though long-term data are lacking.
- The safest route to access PP405 in the UK is through a registered clinical trial via NIHR Be Part of Research or ClinicalTrials.gov.
- Licensed alternatives for hair loss in the UK include topical and oral minoxidil and finasteride 1 mg (for men); a GP or dermatologist should guide treatment choice.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What Is PP405 and How Does It Work for Hair Loss?
PP405 is an investigational topical Wnt pathway activator being studied for androgenetic alopecia; it aims to reactivate dormant follicles and prolong the anagen phase, but remains unlicensed and without large-scale clinical trial data.
PP405 is an investigational topical compound that has attracted interest in hair loss research. It is being explored as a potential treatment for androgenetic alopecia (AGA) — the most common form of hair loss in both men and women — and is reported to work through a distinct mechanism compared to existing licensed therapies such as minoxidil or finasteride.
Not sure if this is normal? Chat with one of our pharmacists →
The compound is understood to act as a Wnt pathway activator. The Wnt signalling pathway plays a critical role in hair follicle development, cycling, and regeneration. In healthy hair growth, Wnt signals help transition follicles from the resting phase (telogen) into the active growth phase (anagen). In individuals experiencing AGA, this signalling can become dysregulated, contributing to follicle miniaturisation and reduced hair density over time.
By targeting this pathway, PP405 aims to reactivate dormant or miniaturised follicles and prolong the anagen phase, potentially resulting in increased hair density and thickness. Unlike finasteride, which works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT) — as described in its Summary of Product Characteristics (SmPC) on the electronic Medicines Compendium (eMC) — PP405 does not appear to act on androgen pathways directly.
It is important to note that the identity of PP405 as a named investigational compound is not yet widely documented in peer-reviewed literature, and the mechanism described above is based on early-stage research. PP405 remains in clinical development and has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). It is not currently available as a licensed treatment in the UK, and evidence from large-scale controlled clinical trials is still emerging. Readers should treat all claims about its efficacy and mechanism with appropriate caution until robust published data are available.
| Feature | PP405 | Minoxidil | Finasteride |
|---|---|---|---|
| Mechanism of action | Wnt pathway activator; reactivates dormant follicles | Vasodilator; prolongs anagen phase via potassium channel opening | 5-alpha reductase inhibitor; reduces DHT conversion |
| Licensed indications (UK) | Not licensed; investigational only — no MHRA authorisation | Androgenetic alopecia (AGA) in men and women | AGA in men only; not licensed for women in the UK |
| Formulation / administration | Topical (investigational); route under clinical evaluation | Topical solution or foam; oral off-label use possible | Oral tablet, 1 mg daily |
| Common side effects | Unknown; possible local irritation, redness, contact dermatitis | Scalp irritation, unwanted facial hair growth, initial shedding | Decreased libido, erectile dysfunction, ejaculation disorders |
| Key warnings | Avoid in pregnancy/breastfeeding; do not source from unregulated suppliers | Avoid contact with eyes; caution in cardiovascular disease with oral use | Teratogenic risk; avoid in women of childbearing potential |
| UK availability | Clinical trials only; search NIHR Be Part of Research or ClinicalTrials.gov | Over the counter (Regaine and generics); oral via private prescription | Typically via private prescription; limited NHS availability |
| Evidence base | Early-stage research only; no large controlled trial data published | Established; multiple RCTs and long-term safety data available | Established; robust RCT evidence for male AGA |
Types of Hair Loss PP405 May Be Used to Treat
PP405 research focuses on androgenetic alopecia in men and women; its potential use in alopecia areata or chemotherapy-related hair loss is speculative and unsupported by clinical trial evidence.
The primary focus of PP405 research to date has been androgenetic alopecia (AGA), also referred to as male-pattern or female-pattern hair loss. According to NICE Clinical Knowledge Summaries (CKS) and the British Association of Dermatologists (BAD), AGA affects approximately 50% of men by the age of 50 and a significant proportion of women, particularly after the menopause. It is characterised by progressive follicle miniaturisation driven by genetic sensitivity to DHT, leading to thinning at the crown and temples in men, and diffuse thinning across the top of the scalp in women.
Because PP405 targets the Wnt signalling pathway rather than androgen activity, researchers have suggested it could be applicable to both male and female patterns of hair loss — potentially addressing a gap in treatment options, particularly for women, for whom finasteride is not licensed in the UK and is generally avoided due to teratogenic risk.
There is theoretical interest in whether Wnt pathway activation could benefit other forms of hair loss involving follicle dormancy, such as alopecia areata (an autoimmune condition) or hair loss following chemotherapy. However, it must be clearly stated that these are speculative possibilities only. There is no clinical trial evidence or regulatory approval supporting PP405 for these indications, and any such applications would require dedicated investigation before any conclusions could be drawn.
Before considering any treatment, patients should seek a formal diagnosis. Hair loss has many causes — including thyroid dysfunction (check TSH), iron deficiency (check ferritin and FBC), nutritional deficiencies, scalp conditions, and medication side effects — many of which are identifiable and treatable. A GP can arrange appropriate investigations in line with NICE CKS guidance on male and female pattern hair loss.
Experiencing these side effects? Our pharmacists can help you navigate them →
Red flags that warrant prompt referral to a dermatologist include:
-
Rapidly progressive or patchy hair loss
-
Scarring of the scalp (scarring alopecias require urgent specialist assessment)
-
Signs of scalp inflammation, scaling, or infection (including tinea capitis, particularly in children)
-
Hair loss in children or adolescents
-
Features of hyperandrogenism in women (e.g. irregular periods, acne, hirsutism)
-
Associated systemic symptoms
The NHS 'Hair loss (alopecia)' page and BAD patient information leaflets provide accessible guidance on when to seek help.
Possible Side Effects and Safety Considerations
PP405's full safety profile is not yet established; as a topical compound, local skin reactions are the primary concern, and it should not be sourced from unregulated online suppliers.
As PP405 is still in clinical development, its full safety and tolerability profile has not yet been comprehensively established in large, long-term studies. No substantial published safety data from controlled trials are currently available in the peer-reviewed literature. The available information from early-phase research suggests that, as a topical formulation, PP405 may have a more localised side effect profile compared to systemic treatments; however, patients and clinicians should approach any investigational compound with appropriate caution.
Potential considerations for topical hair loss treatments in general include:
-
Local skin reactions such as redness, itching, or irritation at the application site
-
Contact dermatitis, particularly in individuals with sensitive skin or known allergies to formulation excipients
-
Unwanted hair growth in areas of unintended contact — a recognised effect seen with topical minoxidil (as noted in its eMC SmPC)
Because PP405 acts on the Wnt signalling pathway — a pathway also involved in cell proliferation — there has been scientific discussion around the theoretical need to monitor for any unintended effects on cell growth with long-term use. It is important to stress that no causal link between PP405 and any serious adverse outcomes has been established in current research, and this remains a theoretical consideration under ongoing investigation.
Pregnancy and breastfeeding: As with all investigational medicines, PP405 should be avoided during pregnancy and breastfeeding unless a patient is enrolled in a clinical trial with explicit regulatory and ethics approval covering this. Individuals who are pregnant, planning a pregnancy, or breastfeeding should discuss hair loss management with their GP or dermatologist.
Patients and healthcare professionals can report suspected side effects from any medicine — licensed or investigational — to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.
From a patient safety perspective, individuals should not attempt to source PP405 through unregulated online channels or overseas suppliers. In the UK, unlicensed medicines ('specials') may only be supplied against a valid prescription by a regulated pharmacy; products obtained outside this framework carry risks related to product quality, concentration accuracy, and contamination. The MHRA publishes guidance on unlicensed medicines for further information. Anyone experiencing unexpected symptoms whilst using any hair loss treatment should contact their GP promptly. Those with a personal or family history of skin cancer or other proliferative conditions should discuss this with a healthcare professional before pursuing novel treatments.
Accessing PP405 in the UK: Prescriptions and Availability
PP405 is not licensed in the UK and cannot be routinely prescribed; the appropriate route is participation in a registered clinical trial found via NIHR Be Part of Research or ClinicalTrials.gov.
At present, PP405 is not licensed for use in the UK and is not available through standard NHS prescribing or high street pharmacies. It does not hold a marketing authorisation from the MHRA, meaning it cannot be routinely prescribed or sold as a medicinal product in the UK. Patients should be aware that any products marketed online as 'PP405' are not subject to the same quality and safety standards as licensed medicines and should be treated with caution.
For those interested in accessing PP405 as part of its development programme, the most appropriate route is through participation in a registered clinical trial. Patients and healthcare professionals can search for relevant studies via:
-
NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) — the primary UK public-facing portal for finding clinical trials
-
ISRCTN Registry (isrctn.com) — a primary registry for UK and international trials
-
ClinicalTrials.gov — a widely used international registry
-
EU Clinical Trials Register / CTIS — for trials conducted within the EU/EEA
Participation in a clinical trial ensures that the compound is administered under medical supervision, with appropriate monitoring and informed consent processes in place. A GP or NHS dermatologist may also be aware of ongoing research opportunities.
In the meantime, several licensed treatments for hair loss are available in the UK and may be suitable depending on the type and cause of hair loss:
-
Minoxidil (topical, available over the counter as Regaine and generics; oral formulations may be prescribed off-label by a clinician with appropriate monitoring — see BNF and eMC SmPC for prescribing information)
-
Finasteride 1 mg (licensed for male AGA; in practice, this is usually obtained via private prescription in the UK rather than NHS prescribing — see the NHS Medicines page on finasteride for current availability information)
-
Dutasteride (used off-label in some cases under clinician supervision; not licensed for AGA in the UK)
Off-label use of oral minoxidil and dutasteride should only be initiated and monitored by a qualified prescriber, given the need to assess contraindications and potential systemic effects.
Patients are encouraged to consult their GP or an NHS dermatology service as a first step for diagnosis and management. Private dermatology clinics can also provide specialist assessment. Trichologists may offer advice on hair and scalp health, but it is important to note that trichology is not a medically regulated profession in the UK — trichologists are not doctors and cannot prescribe medicines or diagnose medical conditions. For any suspected medical cause of hair loss, assessment by a GP or dermatologist is recommended.
NICE CKS topics on male and female pattern hair loss, and BAD patient information leaflets, provide further guidance on the structured assessment and management of hair loss in UK practice. As research into PP405 progresses, updated guidance from the MHRA and other regulatory bodies will provide clearer direction on its potential future role in clinical practice.
Frequently Asked Questions
Is PP405 available to buy or prescribe in the UK?
No. PP405 does not hold a marketing authorisation from the MHRA and cannot be routinely prescribed or purchased through UK pharmacies. The safest way to access it is through a registered clinical trial via NIHR Be Part of Research or ClinicalTrials.gov.
How is PP405 different from minoxidil or finasteride for hair loss?
Unlike minoxidil, which improves scalp blood flow, or finasteride, which blocks DHT production, PP405 targets the Wnt signalling pathway to reactivate dormant hair follicles. This distinct mechanism means it does not directly affect androgen levels, making it of potential interest for both men and women.
What are the known side effects of PP405?
PP405's full safety profile has not yet been established in large controlled trials. As a topical compound, the most likely side effects are local skin reactions such as redness or irritation. It should be avoided during pregnancy and breastfeeding, and should never be sourced from unregulated online suppliers.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
